The trial aims to improve the survival rates for the patients with lung or ovarian cancer. Credit: Nephron

Researchers at Royal Adelaide Hospital in Australia are set to start clinical trials on a new treatment for lung and ovarian cancer.

The breakthrough treatment, expected to improve patients’ survival rates, has secured a funding of A$33m ($22.4m).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will start recruiting patients in early 2020. Researchers at the Royal Adelaide Hospital have partnered with AusHealth.

South Australia health minister Stephen Wade said:  “This partnership, driven by AusHealth, links RAH researchers with pharmaceutical investors and will help to fast track bringing this important technology to patients.

“This trial is the result of almost a decade of research and development at the RAH. The relatively new way to treat cancers has the potential to improve treatment regimens and survival.”

Royal Adelaide Hospital Cancer Clinical Trial Unit head professor Michael Brown said that the treatment deploys APOMAB antibody technology to treat the solid tumours and has the potential to improve the survival rates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Brown said: “The test uses antibodies that carry a low dose of radiation and target a specific protein that is created by dying or dead cancer cells.

“The radiation signal is picked up on a PET scan, so we can see in patients who have received chemotherapy just how well the chemotherapy is killing the cancer cells.

“Our trial aims to test how well the antibodies can target specific cancer cells to deliver low-dose radiation.”

AusHealth managing director and CEO Greg Johansen said: “This is a world-class partnership which is the culmination of a decade of research and development by Professor Brown and his team.

“We look forward to the outcomes of the trial which will evaluate the success of targeted radiation delivery and has the potential to be a breakthrough treatment for solid cancers.”